舒紹坤研究員，入選“長江學(xué)者獎勵計劃”青年學(xué)者項目

美國南佛羅里達(dá)大學(xué)博士畢業(yè)(2010年)，北京大學(xué)腫瘤醫(yī)院研究員，入選教育部“長江學(xué)者獎勵計劃”青年學(xué)者項(2021) 。以第一或責(zé)任作者在《Nature》、《Molecular Cell》等雜志發(fā)表論文。

郵箱：Shaokun_shu@bjmu.edu.cn

主要研究方向、成就

主要從事從事腫瘤轉(zhuǎn)化研究，聚焦在腫瘤新靶點發(fā)現(xiàn)，研究腫瘤抗藥性，開發(fā)聯(lián)合用藥方案等。主要研究成果包括：通過創(chuàng)新性的結(jié)合高通量多組學(xué)手段和大規(guī)模功能基因組篩選平臺，首次鑒定了三陰性乳腺癌特異性的重要致癌靶點基因，在三陰性乳腺癌模型上進行靶向藥物臨床前試驗(Nature, 2016)，研究其作用機理，并進一步研究了腫瘤對靶向藥物的抗藥性機理，找到克服腫瘤抗藥性的聯(lián)合用藥方案 (Molecular Cell，2020)，發(fā)現(xiàn)靶向藥物的生物標(biāo)記物，啟動臨床試驗。把靶向藥物BET抑制劑應(yīng)用到三陰性乳腺癌治療，啟動了二期臨床試驗，同時通過啟動聯(lián)合BET抑制劑和CDK4/6抑制劑，BET抑制劑聯(lián)合PD-L1抗體的臨床試驗。近年來，共發(fā)表SCI收錄學(xué)術(shù)論文10余篇，包括在Nature， Molecular Cell，Nature Cell Biology, Nature Communication等雜志，多項美國專利，啟動和參與兩項二期臨床實驗，課題獲得兩項研究經(jīng)費資助, 4次國際會議獲獎，2次國際會議口頭報告。研究成果被新聞媒體廣泛報道，包括Nature News & Views，F(xiàn)aculty of 1000和 GEN (Genetic Engineering & Biotechnology News)。

承擔(dān)課題

1. 北京大學(xué)臨床醫(yī)學(xué)+X 青年項目 2020-2021

發(fā)表的代表性論文(第一#或責(zé)任作者*)

Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanovi? B, Murphy K, Wang B, Wucherpfennig KW, Qi J, Liu XS, Long H, Brown M, Carroll JS, Brugge JS, Bradner J, Michor F, Polyak K. Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Mol Cell. 2020 May 7. pii: S1097-2765(20)

Ge JY, Shu S, Kwon M, Jovanovi? B, Murphy K, Gulvady A, Fassl A, Trinh A, Kuang Y, Heavey GA, Luoma A, Paweletz C, Thorner AR, Wucherpfennig KW, Qi J, Brown M, Sicinski P, McDonald TO, Pellman D, Michor F, Polyak K. Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nat Commun. 2020 May 11;11(1):2350.

Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Peluffo G, Brown J, D'Santos C, Krop IE, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Wu SY, Chiang CM, Anders L, Young RA, Winer EP, Letai A, Barry WT, Carroll JS, Long HW, Brown M, Liu XS, Meyer CA, Bradner JE, Polyak K. Response and resistance to BET bromodomain inhibitors in triple negative breast cancer. Nature. 2016; 529: 413–417.

Shu S, Polyak K. BET Bromodomain Proteins as Cancer Therapeutic Targets. Cold Spring Harbor Symposia on Quantitative Biology. 2016;81:123-129.

Janiszewska M, Tabassum DP, Casta?o Z, Cristea S, Yamamoto KN, Kingston NL, Murphy KC, Shu S, Harper NW, Del Alcazar CG, Ale?kovi? M, Ekram MB, Cohen O, Kwak M, Qin Y, Laszewski T, Luoma A, Marusyk A, Wucherpfennig KW, Wagle N, Fan R, Michor F, McAllister SS, Polyak K. Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nat Cell Biol. 2019 Jul;21(7):879-888.

Witwicki RM, Ekram MB, Qiu X, Janiszewska M, Shu S, Kwon M, Trinh A, Frias E, Ramadan N, Hoffman G, Yu K, Xie Y, McAllister G, McDonald R, Golji J, Schlabach M, deWeck A, Keen N, Chan HM, Ruddy D, Rejtar T, Sovath S, Silver S, Sellers WR, Jagani Z, Hogarty MD, Roberts C, Brown M, Stegmaier K, Long H, Shivdasani RA, Pellman D, Polyak K. TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer. Cell Reports. 2018 Oct 30;25(5):1255-1267

Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerriero JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, Hilsenbeck S, Schiff R, Osborne KC, Letai A, Polyak K. Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Research. 2016 Nov 15;76(22):6495-6506.